ImmunoPrecise Antibodies Ltd. (HYFT)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Reports Q3 Loss, Lags Revenue Estimates
MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.06 per share a year ago.
MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript
ImmunoPrecise Antibodies Ltd. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SR Swayampakula Ramakanth HC Wainwright & Co. | 29,167.69 | $36,979.28 | $48,126.69 | $11,147.41 | 30.15% |
ImmunoPrecise Antibodies Ltd. (HYFT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ImmunoPrecise Antibodies Ltd. ever had a stock split?
ImmunoPrecise Antibodies Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Jennifer Lynne Bath CEO | NASDAQ (NMS) Exchange | 45257F200 CUSIP |
| CA Country | 102 Employees | - Last Dividend | 23 Nov 2020 Last Split | - IPO Date |
Overview
MindWalk Holdings Corp. is a pioneering bio-native AI company focused on the innovative integration of artificial intelligence with multi-omics data. By leveraging advanced laboratory research techniques, the company aims to expedite the discovery and development of biologics. With its proprietary LensAI platform and HYFT technology, MindWalk collaborates with pharmaceutical and biotechnology firms to minimize risks in drug development and unlock new therapeutic possibilities. Originally founded as ImmunoPrecise Antibodies Ltd., the company underwent a name change to MindWalk Holdings Corp. in September 2025. Established in 1983, it is headquartered in Austin, Texas.
Products and Services
- LensAI Platform
The LensAI platform is at the forefront of MindWalk's technology offerings, employing advanced algorithms to analyze complex biological data. This platform aids in identifying valuable insights that can significantly enhance drug discovery processes.
- HYFT Technology
HYFT technology enables the integration of heterogeneous multi-omics data sources, thus providing a comprehensive understanding of biological systems. This technology supports researchers in drawing valuable correlations and facilitating decision-making processes in drug development.
- Collaborative Partnerships
MindWalk partners with leading pharmaceutical and biotechnology companies, providing them with tailored solutions that streamline their research and development efforts. These collaborations focus on de-risking drug development by leveraging cutting-edge AI technologies and multi-dimensional data analysis.
- Research and Development Support
In addition to its technological platforms, MindWalk offers extensive research and development support. This service encompasses a range of laboratory research capabilities and consulting services aimed at enhancing the efficiency and effectiveness of client projects.
